Histogen, a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, announced that the United States Court of Appeals for the Federal Circuit has affirmed that the Company does not infringe patents in the lawsuit that SkinMedica, Inc. filed against Histogen in 2009.
http://www.prweb.com/releases/2013/8/prweb11059251.htm
http://www.prweb.com/releases/2013/8/prweb11059251.htm
No comments:
Post a Comment